A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) (GA101 & HDMP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02229422 |
Recruitment Status :
Active, not recruiting
First Posted : September 1, 2014
Last Update Posted : September 5, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
CLL | Drug: GA101/HDMP | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Study of Obinutuzumab in Combination With High-Dose Methylprednisolone in Chronic Lymphocytic Leukemia Patients |
Study Start Date : | September 2014 |
Estimated Primary Completion Date : | October 30, 2025 |
Estimated Study Completion Date : | December 25, 2025 |

Arm | Intervention/treatment |
---|---|
Experimental: GA101/HDMP
All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:
All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow: •On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered. |
Drug: GA101/HDMP
All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:
All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow: •On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered. |
- Adverse events that constitute the Dose Limiting Toxicity [ Time Frame: 2 months ]
- Response assessment based on IWCLL [ Time Frame: 2 months ]
- Progression Free Survival [ Time Frame: 2 years ]
- Overall Survival and Minimal residual disease (MRD) [ Time Frame: 2 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of CLL
- Indication for treatment as defined by the IWCLL Guidelines (Hallek et al., 2008b).
- Males and females 18 years of age and older.
-
Laboratory parameters as specified below:
- Hematologic: Hemoglobin > 8 g/dL (may be post-transfusion); platelet count > 40 x103/mm3 (may be post-transfusion). Absolute neutrophil count > 1.0 109 cells/mm3 (Growth factor use is allowed).
- Hepatic: Total Bilirubin < 3 x ULN, and ALT and AST < 3 x ULN
- Renal: Creatinine clearance > 30 mL/min (Calculated according to institutional standards or using Cockcroft-Gault formula. Subjects with requirement of hemodialysis will be excluded).
- ECOG Performance Status < 2, unless the decline of the performance status is considered to be related to CLL symptoms.
- Anticipated survival of at least 6 months.
- Subjects can be enrolled and treated under this protocol regardless of their CLL treatment history or number of previous treatments. In addition, subjects with history of allogeneic stem cell transplant can be enrolled and treated unless they have active manifestations of graft vs. host disease (GVHD) or chronic illness or infections that will prevent them from completing the study.
- Previously untreated subjects that meet ANY of the following criteria: A. Documented refusal to be treated with chemotherapy agents. B. Subjects that are not candidates for treatment with chemotherapy based on poor performance status (ECOG ≥ 2), advance age (> 65 years), Cumulative Illness Rating Scale (CIRS score) ≥ 6 or cytopenias.
- Effective contraception is required while receiving GA101 - Obinutuzumab. For women of childbearing potential and men, effective contraception is required while receiving GA101 - Obinutuzumab and for 365 days (12 months) after the last dose of the study drug.
- Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
- Subjects must give written informed consent to participate in this trial.
Exclusion Criteria:
- Pregnant or nursing women.
- Treatment with chemotherapy, monoclonal antibodies or biological agents (e.g. Ibrutinib, lenalidomide) within 28 days prior to entering the study.
- Treatment with chemotherapy, monoclonal antibodies, biological agents (e.g. Ibrutinib) or other than the investigational agents during the time of participation in this trial.
- Grade 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification.
- Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, COPD)
- Participation in any investigational drug study within 28 days prior to initiation of treatment within this protocol.
- History of second malignancy, other than non-melanoma skin cancer or in situ carcinoma of the cervix or the breast, unless the tumor was successfully treated at least 2 years before trial entry and with no evidence of relapse or active cancer.
- Active symptomatic fungal, bacterial and/or viral infection including evidence of infection with HIV, human T-cell leukemia virus 1 (HTLV-1) seropositive status.
- Evidence of active acute or chronic Hepatitis B (HBV).
- Evidence of active Hepatitis C (HCV): subjects with positive hepatitis C serology AND positive HCV RNA test.
- Any illness or condition that in the opinion of the Investigator may affect safety of treatment or evaluation of any the study's endpoints.
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
- Known hypersensitivity to any of the study drugs.
- Major surgery (within 4 weeks prior to the start of Cycle 1), except for procedures that are performed for diagnostic purposes.
- Men or women of childbearing potential who refuse to use an adequate measure of contraception (oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly) unless they have past medical history of surgical sterilization.
- Vaccination with a live vaccine within 28 days of the initiation of treatment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02229422
United States, California | |
UCSD Moores Cancer Center | |
La Jolla, California, United States, 92093 |
Principal Investigator: | Kipps Thomas, MD | University of California, San Diego |
Responsible Party: | Thomas Kipps, Associate Clinical Professor, University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT02229422 |
Other Study ID Numbers: |
140396 |
First Posted: | September 1, 2014 Key Record Dates |
Last Update Posted: | September 5, 2021 |
Last Verified: | September 2021 |
Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell Leukemia Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases |
Immunoproliferative Disorders Immune System Diseases Leukemia, B-Cell Obinutuzumab Antineoplastic Agents, Immunological Antineoplastic Agents |